Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccines

13 Aug 2022

Abstract excerpt

The Swiss regulatory agency approved BNT 162b2 from Pfizer-BioNTech and mRNA-1273 from Moderna in December 2020 and January 2021, respectively. A third vaccine dose (booster) was recommended by the end of October 2021. Although the vast majority of persons immunized had a good tolerance to the vaccine, a few experienced unexpected adverse reactions, which in rare cases were severe, including hypersensitivity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Bullous Skin Diseases
Share to Drug-Induced Adverse Reactions
Share to Urticaria and Related Conditions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35962744
DOI: 10.1111/cea.14214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccinesPMID 35962744Read ↗

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 VaccinationSemantic proximity Read ↗

Cutaneous Reactions after COVID-19 Vaccines – Analysis of the Clinical and Histological Spectrum – Case Series and Review of the LiteratureSemantic proximity Read ↗

Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staffs with a history of allergySemantic proximity Read ↗

Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS – CoV ‐2 Messenger RNA VaccinationSemantic proximity Read ↗

Immune Characteristics and HLA Associations of SARS-Cov-2 Vaccines-induced Delayed-Type Cutaneous Adverse ReactionsSemantic proximity Read ↗

Management and outcome of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity.Semantic proximity Read ↗

SARS‐CoV‐2 as possible inducer of viral reactivationsSemantic proximity Read ↗

Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis.Semantic proximity Read ↗

SARS-CoV-2 Delta Breakthrough Infections in Vaccinated Patients with Immune-Mediated Inflammatory Diseases Using Immunosuppressants – Data from Two Controlled Prospective Cohort StudiesSemantic proximity Read ↗

Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA VaccineSemantic proximity Read ↗

Rapid Progressive Systemic Sclerosis Following mRNA COVID-19 VaccinationSemantic proximity Read ↗

mRNA-COVID19 vaccination can be considered safe and tolerable for frail patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.